Controlling inflammatory response: Using innovative peptides and nanoparticle technology to significantly reduce the damage and impact on skin of 2nd and 3rd degree burns

控制炎症反应：利用创新肽和纳米颗粒技术，显着减少二度和三度烧伤对皮肤的损伤和影响

• 批准号: 48084
• 金额: $ 34.86万
• 依托单位: CAROCELL BIO LTD
• 依托单位国家: 英国
• 项目类别: Study
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=48084
• 关键词: Controlling; inflammatory; response; Using; innovative

NHS Burns Services treated more than 15,000 patients for burns and scalds in 2017 with costs exceeding £20million and the most severe burns costing £95,000 to treat. The true cost (hospital treatment/operative costs/dressings/staffing/lost productivity/physical and mental health implications) can reach ~£126,000/patient, totaling £1.9billion/year for the UK economy.The resultant acute inflammatory response, whilst fundamental to the healing process, when prolonged can be highly detrimental and lead to scarring and fibrosis which can be disfiguring, functionally restrictive and may require revisionary surgeries. Severe burns may display chronic, persistent inflammation long after initial injury and can even result in multiple organ failure due to systemic inflammatory response syndrome. Therefore, it is imperative that inflammation is effectively managed following burns injuries. Additionally, whilst burn injuries are sterile at time of injury, rapid blistering and necrosis of the injured tissue soon opens the wound up to pathogens and infection risk.The global burns care market is experiencing significant growth (£2.5billion by 2026), dominated by dressings (collagen/hydrogel), traditional burn creams and anti-inflammatory drugs. These current solutions focus only on treating the side-effects of burns, with currently available anti-inflammatories either poorly effective, toxic, causing GI upset, liver/kidney failure and other serious side effects. There is a clear unmet healthcare need for a safer, more specific/effective inflammatory therapeutic.The proposed project seeks to develop a novel peptide medicine delivered using a patented, safe nano-particle delivery technology. Unlike competing solutions this will switch off and prevent the inflammatory response with exquisitely specific inflammation blockers, so only tiny doses will be required to cure serious inflammatory diseases. This will generate significant socio-economic impacts e.g. reduced time and cost of burn treatment to the NHS and patients, reduce the amount the NHS spends on ineffective inflammatory disease treatment and reducing costly health complications.Work to date has focused on initial in-vitro testing demonstrating the lead compound is highly specific, switches off inflammation, prevents activation of inflammation and that nanoparticles are safe in humans' cells. Bridge Biotec have already gained strong interest from mid-level/large pharma placing them in a strong position for licensing and revenue generation within 6 years. It is now critical Bridge Biotec technically advance the solution with this project focusing on development to TRL4 to assess its efficacy in human ex-vivo tissue studies.The project will deliver significant export led growth for Bridge Biotec, a substantial ROI, increased employment and further opportunity for R&D investment.

NHS烧伤服务在2017年治疗了超过15，000名烧伤和烫伤患者，费用超过2000万英镑，最严重的烧伤治疗费用为95，000英镑。（住院治疗/手术费用/敷料/人员配备/生产力损失/身心健康影响）可达到约126，000英镑/患者，由此产生的急性炎症反应，虽然是愈合过程的基础，但当延长时可能是非常有害的，并导致疤痕和纤维化，这可能是毁容的，功能限制性的，并可能需要修复手术。严重烧伤可能在初始损伤后很长时间内表现出慢性、持续性炎症，甚至可能由于全身炎症反应综合征而导致多器官衰竭。因此，在烧伤后有效地控制炎症是至关重要的。此外，虽然烧伤在受伤时是无菌的，但受伤组织的迅速起泡和坏死很快就会使伤口面临病原体和感染风险。全球烧伤护理市场正在经历显着增长（到2026年达到25亿英镑），其中敷料（胶原蛋白/水凝胶）、传统烧伤膏和消炎药占主导地位。这些目前的解决方案仅集中于治疗烧伤的副作用，目前可用的抗炎药要么效果差，有毒，导致GI不适，肝/肾衰竭和其他严重的副作用。有一个明确的未满足的医疗保健需要一个更安全，更具体/有效的炎症治疗。拟议的项目旨在开发一种新的肽药物提供使用专利，安全的纳米颗粒输送技术。与竞争性解决方案不同，这将关闭并阻止炎症反应，并使用精细的特异性炎症阻断剂，因此仅需微小剂量即可治愈严重的炎症性疾病。这将产生重大的社会经济影响，例如减少NHS和患者的烧伤治疗时间和成本，减少NHS在无效炎症疾病治疗上的花费，并减少昂贵的健康并发症。迄今为止的工作集中在初步体外测试上，证明先导化合物具有高度特异性，关闭炎症，防止炎症的激活，纳米颗粒在人类细胞中是安全的。Bridge Biotec已经获得了中型/大型制药公司的强烈兴趣，使他们在6年内处于授权和创收的有利地位。目前，Bridge Biotec在技术上推进该解决方案至关重要，该项目专注于开发TRL 4，以评估其在人体离体组织研究中的功效。该项目将为Bridge Biotec带来显著的出口导向型增长，可观的投资回报率，增加就业机会和进一步的研发投资机会。